Evidence map›Paper›PMID 36072585›Full record

ArticleFrontiers in immunology2022

Aberrant signaling of immune cells in Sjögren's syndrome patient subgroups upon interferon stimulation.

Irene Sarkar, Richard Davies, Anders K Aarebrot, Silje M Solberg, Aleksandra Petrovic, Anagha M Joshi, Brith Bergum, Johan G Brun, Daniel Hammenfors, Roland Jonsson and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Irene SarkarBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Richard DaviesBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Anders K AarebrotBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Silje M SolbergDepartment of Dermatology, Haukeland University Hospital, Bergen, Norway.
Aleksandra PetrovicBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Anagha M JoshiComputational Biology Unit, Department of Clinical Science, University of Bergen, Bergen, Norway.
Brith BergumBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Johan G BrunDepartment of Rheumatology, Haukeland University Hospital, Bergen, Norway.
Daniel HammenforsDepartment of Rheumatology, Haukeland University Hospital, Bergen, Norway.
Roland JonssonBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Silke AppelBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
University of Bergen · NOHaukeland University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease, characterized by mononuclear cell infiltrates in the salivary and lacrimal glands, leading to glandular atrophy and dryness. Patient heterogeneity and lack of knowledge regarding its pathogenesis makes pSS a difficult disease to manage. Methods: An exploratory analysis using mass cytometry was conducted of MAPK/ERK and JAK/STAT signaling pathways in peripheral blood mononuclear cells (PBMC) from 16 female medication free pSS patients (8 anti-Sjögren's syndrome-related antigen A negative/SSA- and 8 SSA+) and 8 female age-matched healthy donors after stimulation with interferons (IFNs). Results: We found significant differences in the frequencies of memory B cells, CD8+ T central and effector memory cells and terminally differentiated CD4+ T cells among the healthy donors and patient subgroups. In addition, we observed an upregulation of HLA-DR and CD38 in many cell subsets in the patients. Upon IFNα2b stimulation, slightly increased signaling through pSTAT1 Y701 was observed in most cell types in pSS patients compared to controls, while phosphorylation of STAT3 Y705 and STAT5 Y694 were slightly reduced. IFNγ stimulation resulted in significantly increased pSTAT1 Y701 induction in conventional dendritic cells (cDCs) and classical and non-classical monocytes in the patients. Most of the observed differences were more prominent in the SSA+ subgroup, indicating greater disease severity in them. Conclusions: Augmented activation status of certain cell types along with potentiated pSTAT1 Y701 signaling and reduced pSTAT3 Y705 and pSTAT5 Y694 induction may predispose pSS patients, especially the SSA+ subgroup, to upregulated expression of IFN-induced genes and production of autoantibodies. These patients may benefit from therapies targeting these pathways.

Indexed as

Leukocytes, MononuclearSjogren's SyndromeFemaleHumansInterferon-alphaSignal TransductionT-LymphocytesInterferon-alphaautoantibodiesmass cytometry (CyTOF)patient stratificationphospho-signalingSjögren’s syndrometype I and type II interferons

Identifiers

PMID36072585
PMCPMC9441756
OpenAlexW4292553287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.